SCHEMBL13373154

SCHEMBL13373154

Cc1ccc(C)c(S(=O)(=O)N2CCN(C(=O)c3cccnc3C)[C@@H](C)C2)c1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.53
ALDH1A1 P00352 3/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
TDP1 Q9NUW8 2/20 0.47
USP2 O75604 1/20 0.47
TSHR P16473 1/20 0.47
NPC1 O15118 2/20 0.46
LMNA P02545 2/20 0.46
HTT P42858 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MITF O75030 1/20 0.46
MAPK1 P28482 1/20 0.46
GAA P10253 1/20 0.45
HCRTR1 O43613 2/20 0.42
HCRTR2 O43614 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12965697 0.88 IDH1 (0.40) RAB9AALDH1A1SMN1; SMN2L3MBTL1HTT
SCHEMBL13373122 0.85 TSHR (0.50) ALDH1A1SMN1; SMN2TSHRLMNAKDM4E
SCHEMBL13373241 0.83 L3MBTL1 (0.62) RAB9AALDH1A1SMN1; SMN2L3MBTL1TDP1
SCHEMBL12965392 0.83 GAA (0.42) SMN1; SMN2GAAHCRTR1HCRTR2
SCHEMBL13373120 0.82 TDP1 (0.50) RAB9AALDH1A1SMN1; SMN2L3MBTL1TDP1
Hydrochloric Acid SCHEMBL1430239 0.82 GAA (0.41) SMN1; SMN2GAAHCRTR1HCRTR2
Cnv2197944 SCHEMBL12965609 0.77 HSD11B1 (0.48) ALDH1A1TDP1GAA
Cnv2197944 SCHEMBL1429576 0.77 HSD11B1 (0.48) ALDH1A1TDP1GAA
Cnv2197944 SCHEMBL18652790 0.77 HSD11B1 (0.48) ALDH1A1TDP1GAA
Cnv2197944 SCHEMBL1429858 0.77 HSD11B1 (0.48) ALDH1A1TDP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536183-B2 3-pyridylcarbonyl-piperazinylsulfonyl derivatives Convergence Pharmaceuticals Limited (GB) 2013-09-17 US disclosed
US-20120302746-A1 3-PYRIDYLCARBONYL-PIPERAZINYLSULFONYL DERIVATIVES BESWICK PAUL JOHN (GB) 2012-11-29 US disclosed
US-8288388-B2 3-pyridylcarbonyl-piperazinylsulfonyl derivatives Convergence Pharmaceuticals Limited (GB) 2012-10-16 US disclosed
US-20100022555-A1 Novel Derivatives Convergence Pharmaceuticals Limited (GB) 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022555-A1 Novel Derivatives CACNB2, CACNA1B, CACNA1D RAB9A 2604/4885ALDH1A1 3984/4885SMN1; SMN2 809/4885
US-20120302746-A1 3-PYRIDYLCARBONYL-PIPERAZINYLSULFONYL DERIVATIVES CACNB2, CACNA1C, KCNJ2 RAB9A 2717/4885ALDH1A1 3994/4885SMN1; SMN2 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.